Increasing microcirculation after drotrecogin alfa (activated)

Increasing microcirculation after drotrecogin alfa (activated)

Bibliographic Details
Main Authors:	Donati, A, Romanelli, M, Romagnoli, L, Ruzzi, M, Beato, V, Gabbanelli, V, Nataloni, S, Principi, T, Pelaia, P
Format:	Online
Language:	English
Published:	BioMed Central 2007
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4095109/

Similar Items

The safety profile of drotrecogin alfa (activated)
by: Fumagalli, Roberto, et al.
Published: (2007)

Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
by: Dhainaut, J, et al.
Published: (2008)

Clinical trials in severe sepsis with drotrecogin alfa (activated)
by: Laterre, Pierre-François
Published: (2007)

Practical aspects of treatment with drotrecogin alfa (activated)
by: Camporota, Luigi, et al.
Published: (2007)

Introduction: severe sepsis and drotrecogin alfa (activated)
by: Artigas, Antonio, et al.
Published: (2007)

Retrospective observational outcomes for drotrecogin alfa (activated)
by: Cameron, C, et al.
Published: (2007)

Drotrecogin alfa (activated): down and not out, but not really in either
by: Friedrich, Jan O, et al.
Published: (2006)

Timing of drotrecogin alfa (activated) treatment in severe sepsis
by: Choi, Goda, et al.
Published: (2006)

Use of national guidelines for the introduction of Drotrecogin alfa (activated)
by: Mackenzie, S, et al.
Published: (2004)

Drotrecogin alfa (activated) for the treatment of severe sepsis in adults
Published: (2006)

A large, single-centre UK registry of drotrecogin alfa-activated use
by: Macchiavello, L, et al.
Published: (2007)

Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry
by: Beale, R, et al.
Published: (2007)

Tissue perfusion evaluation with near-infrared spectroscopy during treatment with activated protein C
by: Donati, A, et al.
Published: (2008)

Multicentre audit of the use of drotrecogin alfa (activated) in UK critical care units
by: Rowan, K, et al.
Published: (2007)

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
by: Levy, Howard, et al.
Published: (2005)

Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis
by: Jamdar, Saurabh, et al.
Published: (2005)

Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death
by: Friedrich, Jan O, et al.
Published: (2006)

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
by: Bernard, Gordon R, et al.
Published: (2003)

Drotrecogin alfa (activated) does not impair platelet receptor expression in vitro
by: Schuerholz, T, et al.
Published: (2004)

Non-invasive assessment of cardiac index: comparison between PiCCO and LiDCO
by: Donati, A, et al.
Published: (2006)

Near-infrared spectroscopy StO2 monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock
by: Masip, Jordi, et al.
Published: (2013)

Drotrecogin alfa: start early, ensure response, stop early!
by: Jog, S, et al.
Published: (2008)

Eligibility for drotrecogin alfa therapy on the basis of APACHE II score and organ failure
by: Shulman, R, et al.
Published: (2005)

Gene array transcript profiling of human endothelial cells identifies pathways regulated by Drotrecogin alfa (activated)
by: Brueckmann, M, et al.
Published: (2003)

Neuroaxial catheters following abdominal surgery and their impact on the use of Drotrecogin alfa (activated) in sepsis
by: Steel, A, et al.
Published: (2004)

Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
by: Costa, Vania, et al.
Published: (2007)

Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients
by: Launois, R, et al.
Published: (2002)

Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
by: Sadique, M Zia, et al.
Published: (2011)

Three years experience with drotrecogin alfa (activated) protein C in severe sepsis and septic shock at Salmaniya Medical Complex, Bahrain
by: Mohamed, H, et al.
Published: (2007)

Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death
by: Williams, Mark D, et al.
Published: (2006)

New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated)
by: Macias, William L, et al.
Published: (2005)

Testing of anti-activated protein C antibodies in four drotrecogin alfa (activated) severe sepsis studies
by: Yan, S, et al.
Published: (2008)

From Macrohemodynamic to the Microcirculation
by: Donati, Abele, et al.
Published: (2013)

Drotrecogin alfa in patients with severe sepsis: experience from a tertiary care center in North India
by: Chawla, R, et al.
Published: (2007)

Treatment of Severe Sepsis: Where Next? Current and Future Treatment Approaches After the Introduction of Drotrecogin Alfa
by: Rice, Todd W
Published: (2006)

Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
by: Vincent, Jean-Louis, et al.
Published: (2006)

Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)
by: Shorr, Andrew F, et al.
Published: (2010)

Variation of hemodynamic parameters after fluid challenge
by: Donati, A, et al.
Published: (2008)

Audit of adherence to National Institute of Clinical Excellence guidelines for the use of drotrecogin alfa (activated)
by: Vedantham, R, et al.
Published: (2007)

Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?
by: Friedrich, Jan O, et al.
Published: (2006)